Coloplast A/s Class B · OMXCOP:COLO_B
Coloplast A/s Class B — Investor Day (August 2019)
80 slides from Coloplast A/s Class B's investor day presentation, Aug 20, 2019
Slide 1: Coloplast Meet the Management
Our mission Making life easier for people with intimate healthcare needs Coloplast Meet the Management 20 August 2019 Making life easier Ostomy Care, Continence Care, Wound & Skin Care and Interventional Urology
Slide 2: Agenda
Agenda Welcome & Q3 2018/19 presentation 11:00 – 11:15 Group strategy update 11:15 – 12:30 Lunch buffet 12:30 – 13:15 Q&A breakout session #1 13:15 – 14:05 10 minute break 14:05 – 14:15 Q&A breakout session #2 14:15 – 15:05 Coffee break 15:05 – 15:35 Q&A breakout session #3 15:35 – 16:25 10 minute b
Slide 3: Q3 18/19 results presentation
Making it easier_ Q3 18/19 results presentation to follow your heart Coloplast Meet the Management London 2019 I felt lonely and incomplete when I wasn’t capable of 20 August 2019 sex. Since I found a solution, I have started dating again and my life has opened up. Making life easier Ostomy Care, Co
Slide 4: Forward-looking statements
Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements
Slide 5: Coloplast delivered Q3 organic growth of 8% and an EBIT margin of 31%
Making life easier Coloplast delivered Q3 organic growth of 8% and an EBIT margin of 31% Q3 Highlights Revenue growth +9% • Organic growth of 8% and 9% in DKK Reported revenue (DKKm) +8% • Continued strong momentum in Europe across all business Organic growth 13,321 areas and double digit growth in
Slide 6: Solid growth across all business areas in Europe, US and China
Making life easier Solid growth across all business areas in Europe, US and China 9M 18/19 revenue by business area 9M 18/19 revenue by geography Business Reported revenue Organic growth Share of organic Geographic Reported revenue Organic growth Share of organic area DKKm growth area DKKm growth Os
Slide 7: Solid growth in EBIT of 11% in 9M and 13% in Q3
Making life easier Solid growth in EBIT of 11% in 9M and 13% in Q3 Comments EBIT margin development (%) • EBIT increased 11% to DKK 4,077m with a reported margin of 31% compared to 30% last year • Gross margin of 67% in DKK compared to 67% same period last year 0.1 -0.2 0.0 30.6 0.0 30.6 0.0 • Posit
Slide 8: FCF driven by solid underlying development in earnings
Making life easier FCF driven by solid underlying development in earnings and acquisitions in comparison period FCF development Comments • Free cash flow in 9M 2018/19 was DKK 2,215m, up 11% compared to DKK 1,988m in 9M 2017/18 98 99 • The increase is mainly explained by a decrease in investment act
Slide 9: Unchanged guidance for FY 2018/19
Making life easier Unchanged guidance for FY 2018/19 Guidance 2018/19 Guidance 2018/19 (DKK)* Key assumptions • Up to 1% negative price pressure from Switzerland, Holland and Sales growth ~8% ~9% the French price reform (organic) • DKK guidance includes growth from Lilial and IncoCare • Incremental
Slide 10: Group Strategy update
Making it easier_ to be one of the girls My stoma doesn’t define me. My friends know about it and they support me. I feel comfortable when we are hanging out. Group Strategy update Coloplast Meet the Management London 2019 Kristian Villumsen, President & CEO Making life easier Ostomy Care, Continenc
Slide 11: What we would like to share with you today
Making life easier What we would like to share with you today We have successfully accelerated growth and value creation through our LEAD20 strategy We are building the consumer healthcare company of the future, while pursuing and investing in the numerous growth levers we see in our markets We have
Slide 12: Our LEAD20 strategy has successfully accelerated growth and value creation
Making life easier Our LEAD20 strategy expires next year and has successfully accelerated growth and long-term value creation LEAD20 strategy Long-term guidance Financial performance 17/18-19/20 Organic growth, EBIT (%) & ROIC (%) Full year Quarter Revenue growth annual organic 8% 8% ~8% 7% 7% 7–9%
Slide 13: Today, Coloplast has four business areas
Making life easier Today, Coloplast has four business areas all with global sales presence and attractive sub-categories Ostomy Continence Wound & Skin Interventional Care ~45% Care Care Urology of revenue ~40% ~35% ~15% ~10% of revenue of revenue of revenue of revenue Bags & Plates Intermittent Cat
Slide 14: We are building the consumer healthcare company of the future
Making life easier We are building the consumer healthcare company of the future… Superior Clinical Consumer Payer products & preference preference preference innovation Care, DtC & Direct Data and digital tools Page 5
Slide 15: Pursuing numerous growth drivers across our markets
Making life easier …and pursuing numerous growth drivers across our markets Growth Drivers 1 Build & shape reimbursement categories 2 Introduce superior innovation and value upgrade 3 Invest in geographies with untapped potential 4 Drive penetration & support users to improve QoL Pursue category lea
Slide 16: Balanced investment strategy to fuel growth
Making life easier To fuel growth & sustain long-term competitive advantage, our investment strategy has a balanced approach Up to 2% of sales invested annually across… …functions …geographies …and time horizons 15/16-18/19 15/16-18/19 Short term: Sales force, marketing and infrastructure • Optimize
Slide 17: Short-term commercial investments are largely on track
Making life easier …and our short-term commercial investments are largely on track Investment focus Status Innovation (✓) Chronic Care ✓ Wound Care ✓ Interventional Urology ✓ Page 8
Slide 18: Our product portfolio is the strongest to date
Making life easier Our product portfolio is the strongest to date Ostomy Care Continence Care Wound & Skin Care Interventional Urology Page 9
Slide 19: Users still face problems in their daily life
Making life easier But users still face problems in their daily life – we have more work to do Intermittent Erectile 91% catheter users have dysfunction of people with a stoma worry about 2.7 Up to 28% 350 may affect nearly leakage urinary of diabetic foot wounds million and 76% have tract may resul
Slide 20: User needs are at the centre of innovation
Making life easier User needs are at the centre of all our innovation activities and service offerings Page 11
Slide 21: Build & shape reimbursement categories
Making life easier Build & shape reimbursement categories Growth Drivers 1 Build & shape reimbursement categories 2 Introduce superior innovation and value upgrade 3 Invest in geographies with untapped potential 4 Drive penetration & support users to improve QoL Pursue category leadership in Silicon
Slide 22: Making it easier to get back on track
Making it easier_ to get back on track It took a while but know I have taken back control. I’m trying new things, pushing my limits again. Build & shape reimbursement categories Coloplast Meet the Management London 2019 Christian Bo Petersen, Senior Vice President, Payers & Trade Making life easier
Slide 23: Integrated & upscaled Market Access approach
Making life easier GROWTH DRIVER 1: INTRODUCE & SHAPE REIMBURSEMENT CATEGORIES We have integrated & significantly upscaled our Market Access approach Significant upscale of the function … and fully integrated into core processes • Direct reporting to EXM / Country Managers • Reimbursement & Pricing
Slide 24: Roadmap to premium/new reimbursement categories
Making life easier GROWTH DRIVER 1: INTRODUCE & SHAPE REIMBURSEMENT CATEGORIES Our roadmap to premium/new reimbursement categories begins with unmet user needs or medical problems Sequence of introducing & shaping reimbursement categories 1: Identify unmet need 3: Link value drivers to 5: Apply for
Slide 25: Health economic modelling informs payers
Making life easier GROWTH DRIVER 1: INTRODUCE & SHAPE REIMBURSEMENT CATEGORIES Health economic modelling inform payers of estimated costs of an illness – and potential treatment costs/savings Health Economic Modelling Interview HCPs Define current practice Develop, populate and publish model 1000 Se
Slide 26: Annual spend on Peristomal Skin Complications in UK
Making life easier GROWTH DRIVER 1: INTRODUCE & SHAPE REIMBURSEMENT CATEGORIES Example: Annual spend on Peristomal Skin Complications in UK has been estimated via a published HE model(1) An ileostomist in UK (vs. SenSura Mio, Flat, 1pc user) Skin complications(1) With a prevalence of Peristomal Prod
Slide 27: Burden of illness studies inform payers
Making life easier GROWTH DRIVER 1: INTRODUCE & SHAPE REIMBURSEMENT CATEGORIES Burden of illness studies inform payers of real costs of an illness – and saving potentials Real world evidence: Burden of illness studies User journey 1 ….. ….. ….. ….. ….. Select vendor / Define data points Data extract
Slide 28: Burden of illness study in Germany
Making life easier GROWTH DRIVER 1: INTRODUCE & SHAPE REIMBURSEMENT CATEGORIES Example: Results from a burden of illness study in Germany show significant payer costs linked to ostomates Data Total cost per year Total cost split ostomates(1) EUR Inpatient Stoma products German claims database Colost
Slide 29: Introduce superior innovation and value upgrade
Making life easier Introduce superior innovation and value upgrade Growth Drivers 1 Build & shape reimbursement categories 2 Introduce superior innovation and value upgrade 3 Invest in geographies with untapped potential 4 Drive penetration & support users to improve QoL Pursue category leadership i
Slide 30: Making it easier to get lost in the moment
Making it easier_ To get lost in the moment For some time I was too nervous to play in front of others. But now I’ve got my confidence back. When I play, I feel free. Introduce superior innovation and value upgrade Coloplast Meet the Management London 2019 Oliver Johansen, SVP Global R&D Making life
Slide 31: Raise the standard of care through clinically superior products
Making life easier GROWTH DRIVER 2: INTRODUCE SUPERIOR INNOVATION AND VALUE UPGRADE We want to raise the standard of care through clinically superior products and innovation Clinical superior innovation User needs are at the centre of all our innovation activities and service offerings Page 22
Slide 32: Strengthened pre-clinical capabilities and more clinical studies
Making life easier GROWTH DRIVER 2: INTRODUCE SUPERIOR INNOVATION AND VALUE UPGRADE We have strengthened our pre-clinical capabilities and are running more clinical studies to test new technologies Phase of clinical studies: Test new technologies and accelerating development Number of clinical studi
Slide 33: Peristomal skin complications are common and costly
Making life easier GROWTH DRIVER 2: INTRODUCE SUPERIOR INNOVATION AND VALUE UPGRADE Today we will focus on Ostomy Care where peristomal skin complications are common and a burden for many users and costly to payers and society Peristomal skin complications is a real cost driver And is a burden for m
Slide 34: Pilot study shows significant peristomal skin improvement
Making life easier GROWTH DRIVER 2: INTRODUCE SUPERIOR INNOVATION AND VALUE UPGRADE Pilot study shows significant peristomal skin improvement and supports our premium price ambition* Testing new skin protecting technology in Pilot study* Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 (Inclusion) (T
Slide 35: Using AI for peristomal skin analysis
Making life easier GROWTH DRIVER 2: INTRODUCE SUPERIOR INNOVATION AND VALUE UPGRADE We are using artificial intelligence (AI) for peristomal skin analysis Using AI for peristomal skin analysis • During our clinical studies users take pictures of their peristomal area and base plate when changing the
Slide 36: Digital efforts progressing in detecting leakage
Making life easier GROWTH DRIVER 2: INTRODUCE SUPERIOR INNOVATION AND VALUE UPGRADE Our digital efforts are progressing and pilot studies have showed encouraging results in detecting leakage (1,2) Our digital aspiration Giving users accurate information about product performance • We have a strong c
Slide 37: Protecting our Intellectual Property is important
Making life easier GROWTH DRIVER 2: INTRODUCE SUPERIOR INNOVATION AND VALUE UPGRADE We have raised the bar for innovation and protecting our Intellectual Property is important Number of patents published(1) – Chronic Care Patented areas 50 Digital health 40 30 Skin protecting technology 20 10 New IC
Slide 38: Incremental and next level innovation
Making life easier GROWTH DRIVER 2: INTRODUCE SUPERIOR INNOVATION AND VALUE UPGRADE We have a strong track record in delivering incremental innovation and are making good progress on next level innovation Incremental innovation Next level innovation New products and line extensions within existing C
Slide 39: Next steps
Making life easier Next steps In Ostomy Care we will continue to: • Conduct pilot and pivotal clinical studies in order to • Show efficacy and safety to be used for price and category negotiations • Support product registration and product claims • Drive our digital efforts In Continence Care we are
Slide 40: Remaining growth drivers
Making life easier Now, let’s have a closer look at the remaining growth drivers that we see Growth Drivers 1 Build & shape reimbursement categories 2 Introduce superior innovation and value upgrade 3 Invest in geographies with untapped potential 4 Drive penetration & support users to improve QoL Pu
Slide 41: Selectively invest in attractive geographical regions
Making life easier GROWTH DRIVER 3: INVEST IN GEOGRAPHIES WITH UNTAPPED POTENTIAL We will selectively invest in attractive geographical regions – strong focus on further scaling our US and CN businesses European markets Select investments to pursue pockets of growth In attractive markets like UK, DE
Slide 42: Consumer focus supports users across countries
Making life easier GROWTH DRIVER 4: DRIVE PENETRATION & SUPPORT USERS IMPROVE QOL Our consumer focus enables us to support users across countries to live the life that they want Over 1m consumers in 30+ countries through Care and DtC Increasing Direct presence Enabling users through digital platform
Slide 43: Committed to Wound Care investment
Making life easier GROWTH DRIVER 5: PURSUE CATEGORY LEADERSHIP IN SILICONE We are committed to Wound Care and have invested in innovation and commercial initiatives to scale the business Attractive market Investing in commercial AWC market continues to grow and activities and launching we are well p
Slide 44: Interventional Urology outpaces the market
Making life easier GROWTH DRIVER 6: SCALE AND SUSTAIN STRONG PROFITABILITY IN INTERVENTIONAL UROLOGY In Interventional Urology, we continue to outpace the market with a comprehensive portfolio of solutions Growth fueled by investments Strategy and focus in commercial expansion Efficiently delivered,
Slide 45: Growing in a socially responsible way
Making life easier We will continue to strive to grow our business in a socially responsible way, and reduce our environmental impact By empowering people By acting respectfully Access to Healthcare Inclusion & diversity 52 20% projects supported Women in top management since 2007 Coloplast Care Bus
Slide 46: In summary
Making life easier In summary We have successfully accelerated growth and value creation through our LEAD20 strategy We are building the consumer healthcare company of the future, while pursuing and investing in the numerous growth levers we see in our markets We have the strongest product portfolio
Slide 47: Chronic Care update
Making it easier_ to be yourself Clothes are a part of my identity, so I worried about what I could wear after my operation. Today, I still dress the way I want. Chronic Care update Coloplast Meet the Management London 2019 Paul Marcun, EVP Chronic Care Manu Varma, SVP Chronic Care North America Mak
Slide 48: Chronic Care represents more than 75% of sales
Making life easier Chronic Care represents more than 75% of Coloplast sales and we continue to outgrow the market Chronic Care sales, in DKK FY 17/18 >75% Chronic Care reported sales growth vs. market by BA, % FY 17/18 of Coloplast sales 9% 8% 12.6 billion of DKK annual sales 5-6% 4-5% Chronic Care
Slide 49: Outgrowing the market across all regions
Making life easier We are outgrowing the market across all regions Chronic Care sales growth vs. market by region, % 18/19 Q1-Q3 Europe Other developed markets Emerging Markets Market growth Coloplast growth Market growth Coloplast growth Market growth Coloplast growth Performance drivers Performanc
Slide 50: Ambition to grow faster than the market
Making life easier Our ambition remains to grow faster than the market driven by our 3 strategic themes Our revenue ambition is to outgrow the market Our strategic themes Market growth - Annual 1 5% - 6% 4% - 5% 2 OC CC 3 Source: Coloplast Page 4
Slide 51: New product launches and upgrades drive growth
Making life easier 1 SUPERIOR AND CLINICALLY DIFFERENTIATED PRODUCTS New product launches and upgrades contribute significantly to our growth Innovative products Key growth drivers Growth continuous to be driven by SenSura® Mio SenSura® Mio portfolio Convex Win with SenSura® SenSura® Mio Concave now
Slide 52: SenSura Mio Concave solves an unmet need
Making life easier 1 SUPERIOR AND CLINICALLY DIFFERENTIATED PRODUCTS SenSura® Mio Concave solves an unmet need for people with outward body profiles Unmet needs Innovative features UK SenSura Mio Concave consumption analysis 83% o SenSura Mio Concave launched in the UK with outward body profile in A
Slide 53: DtC, Care and Direct presence
Making life easier 2 UNIQUE CONSUMER RELATIONSHIP Our DtC, Care and Direct presence gives us a close relationship with our consumers Global Coloplast DtC and Care presence We are now Direct in our largest markets Over 1M consumers in our database Over 1M conversations with users across the globe Ove
Slide 54: Revenue growth outpacing the US market
Making life easier 3 NEXT LEVEL COMMERCIAL EXECUTION Revenue growth outpacing the US market as new strategy drives results Coloplast sales vs. market growth Key growth drivers 17/18 – 18/19 YTD 2x 2x ~4% ~4% Market Coloplast Market Coloplast Growth ambition Ostomy Care Continence Care +10% Sources:
Slide 55: Ostomy Care: share gains in acute and home health
Making life easier 3 NEXT LEVEL COMMERCIAL EXECUTION In Ostomy Care, continuing to gain share in acute and increasing focus on the home health channel US Ostomy patient pathway Continuing to gain share in the acute channel Patients +7 pts. Hospital 3-5 days 15/16 16/17 17/18 Recent acute contract wi
Slide 56: Hospital purchases via direct or GPO contracts
Making life easier 3 NEXT LEVEL COMMERCIAL EXECUTION In Ostomy Care, most hospitals’ purchases are made either directly or through GPO contracts Representative GPO bidding process Near term contract detail for top three GPOs by annual spend GPO bid Estimated Next Acute Acute contract Members(1) shar
Slide 57: Making hydrophilics the market standard
Making life easier 3 NEXT LEVEL COMMERCIAL EXECUTION In Continence Care, we are making hydrophilics the market standard Hydrophilics becoming the standard Expanding to drive growth Securing innovative product access IC sales force expansion and strong patient service Hydrophilics share of Business m
Slide 58: Investing in Emerging Markets
Making life easier 3 NEXT LEVEL COMMERCIAL EXECUTION In Emerging Markets we continue to invest in order to reach our ambition of 15-20% growth Emerging Markets at a glance Build on market leading position in China • SenSura® upgrade and accessories focus • Expansion of sales force to extend call poi
Slide 59: Wound Care update
Making it easier_ Wound Care update Coloplast Meet the Management London 2019 Nicolai Buhl Andersen, SVP Wound and Skin Care to stay active I love taking my boat out and I do so whenever I can. Sometimes the weather stops me. But I won’t let my condition stop me. Making life easier • . Ostomy Care,
Slide 60: The global AWC market remains large and growing
Making life easier The global AWC market remains large and growing The Advanced Wound Care market remains a significant Silicone Foams and Gelling Fibers are the two biggest value pool and continues to grow across all regions categories and main growth contributors Market size in DKKbn Emerging Sili
Slide 61: Investing in and executing our Wound Care strategy
Making life easier We continue to invest in and execute on our strategy for Wound Care Shape the Endorsements Publications standard Build a strong product PIP portfolio Accelerate in Ramp-up EU Strengthen New structure New New position in the management Investment plan US Secure leading position New
Slide 62: Wound Management is about exudate management
Making life easier Our approach to Wound Care is driven by our belief that good Wound Management is all about exudate management Gaps create space for Pools of exudate may lead to If exudate leaks onto the wound exudate pooling bacterial growth and the edges and periwound skin, risk of infection the
Slide 63: Biatain Silicone with 3DFit Technology
Making life easier Biatain® Silicone with 3D Fit® Technology is a strong offering within exudate management 3DFit Technology is unique Strong customer feedback Category leadership Biatain® Silicone leading silicone brand in Hospital channel Coloplast Biatain® Silicone leading silicone brand in key s
Slide 64: And we can show that it works
Making life easier And we can show that it works Scientific evidence…. … with positive patient outcomes .. and cost effectiveness Proprietary technology(1) Retrospective case series of ISPOR Published Budget 104 wounds(4): model(6) Conforms to the wound bed, absorb vertically, and retain 100% confor
Slide 65: Expanding offerings for deep wounds with Biatain Fiber
Making life easier We are expanding our offerings to address deep wounds with Biatain® Fiber with HexaLock® Technology To reduce exudate pooling requires a dressing that conforms to the wound bed Wounds less than 2 cm Cavity wounds, undermining, highly exuding and sloughy wounds • . Page 7
Slide 66: Biatain Fiber with HexaLock Technology
Making life easier Biatain® Fiber with the unique HexaLock® Technology • . Page 8
Slide 67: Biatain Fiber with HexaLock Technology
Making life easier Biatain® Fiber with the unique HexaLock® Technology Exudate management Unique technology Key benefits Biatain Fiber Key competitor To reduce exudate pooling a gelling fiber needs to have: Less risk of maceration due to hexagonal shape 1. Optimal absorption 2. Optimal retention Min
Slide 68: Expanding our portfolio
Making life easier By expanding our portfolio, we are improving our relevance and competitiveness For non- infected wounds Biatain® Silicone Biatain® Silicone Lite Biatain® Biatain® Fiber Biatain® Alginate Biatain® Contact Biatain® Super For infected and painful wounds Biatain® Silicone Ag Biatain®
Slide 69: YTD 18/19 performance: 8% growth for Wound Care
Making life easier YTD 18/19 performance picture: 8% growth for Wound Care • Positive performance across all markets • Growing faster than the market • Strong silicone performance • Positive Q3 performance for WSC • Growing faster than • Positive performance the market • Growing faster than the mark
Slide 70: Our key messages
Making life easier Our key messages: • The AWC market remains • Biatain® Silicone with • We are expanding our • We are pleased with our significant and continues 3D® Fit Technology portfolio to complete our YTD performance to grow continues to prove its exudate management clinical relevance offering
Slide 71: Finance & Global Operations
Making it easier_ to go all in I lost 35 kilos when I was ill. But I have put it all back on. I fell determined, I’m training regularly and I have now opened my own gym Finance & Global Operations Coloplast Meet the Management London 2019 Anders Lonning-Skovgaard, EVP & CFO Allan Rasmussen, EVP Glob
Slide 72: Q4 2018/19 growth outlook
Making life easier In Q4 2018/19, growth to be driven by US and Europe ex. France, but impacted by Emerging markets weakness Revenue development (DKKm) Drivers of organic growth in Q4 956 55 95 13,321 2018/19 Growth will be positively impacted by: + Continued good growth in the US and 12,215 Europe
Slide 73: Q4 2018/19 EBIT margin drivers
Making life easier In Q4 2018/19, EBIT will be positively impacted by operating leverage and initial savings from Global Operations Plan 4 EBIT margin development (%) Drivers of EBIT margin in Q4 2018/19 0.1 -0.2 0.0 30.6 0.0 30.6 0.0 EBIT will be positively impacted by: + Leverage effect on fixed c
Slide 74: Strong and stable earnings and cash conversion
Making life easier We will continue to deliver strong and stable earnings and cash conversion … Gross margin Distribution costs Administration costs R&D costs % of revenue % of revenue % of revenue % of revenue 68.3 68.1 67.3 67.4 28.1 28.1 28.7 29.1 28-30 3.8 4.0 4.0 4.0 ~4 3.9 3.9 ~4 3.5 3.7 15/16
Slide 75: Attractive cash returns to shareholders
Making life easier …and continue to provide attractive cash returns despite large investments in commercial and expansion activities Coloplast cash distribution to investors Dividends paid out in the year (mDKK) (1) Share buy-back (DKKm) Pay-out ratio (%) (2) 100 88 84 78 77 82 77 We will continue t
Slide 76: Excellence within Business Support
Making life easier Continued excellence within Business Support enables Coloplast to scale faster and more efficiently Global Business Services Recent improvements/investments in Global Business Services UK Prescription handling (Global support center) Global Business Support Centre MDR/regulatory s
Slide 77: GOP4 is on track to deliver 150bps
Making life easier The GOP’s have delivered significant value creation for more than 10 years and GOP4 is on track to deliver 150bps Global Operations Plan 4 GOP 4 EBIT margin contribution, bps 50 100 GOP 3 GOP 2 19/20E 20/21E GOP 1 Restructuring costs (GOP 3 & 4) DKKm 50 43 Turn around 20 20 15/16
Slide 78: GOP4 is progressing well across all key initiatives
Making life easier GOP4 is progressing well across all key initiatives 1 Build a new volume site in Americas 2 Ramp-up activities discontinued in DK and established in Hungary 3 Focus on cost improvements in procurement Expand machine building activities in Zhuhai and establish machine 4 commissioni
Slide 79: Global Operations Plans deliver unparalleled efficiency
Making life easier The Global Operations Plans will continue to deliver unparalleled efficiency Cost of sales Examples of themes under Global Operations Plan’s FY 2017/18 9% 21% 12% Automation 9% DKK 5,383m Diversification (Costa Rica) 49% Salary - Direct Salary - Indirect Procurement Materials (RM
Slide 80: Our mission, values and vision
Our mission Making life easier for peoplé with intimate healthcare needs Our values Closeness... to better understand. - Passion... to make a difference Respect and responsibility... to 0 guide | US: Our vision Setting the global standard for listening and responding: Coloplast Group - Ostomy Care /